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Abstract Human somatic stem cells such as mesenchymal
stem cells (hMSCs) have the capacity to differentiate into mes-
enchymal tissue lineages and to alter immune regulatory func-
tions. As such, they hold promise for use in stem cell-based
therapies. However, nomethod is currently available to evaluate
the actual differentiation capacity of hMSCs prior to cell trans-
plantation. Previously, we performed a comprehensive glycan
profiling of adipose-derived hMSCs using high-density lectin
microarray and demonstrated that α2–6-sialylation is a marker
of the differentiation potential of these cells. Nevertheless, no
information was available about the structural details of these of
α2–6-sialylated glycans. Here we used high performance liquid
chromatography (HPLC) analysis combined with mass spec-
trometry (MS) to perform a structural and quantitative glycome
analysis targeting both N- and O-glycans derived from early
(with differentiation ability) and late (without differentiation
ability) passages of adipose tissue-derived hMSCs. Findings in
these cells were compared with those from human induced plu-
ripotent stem cells (hiPSCs), human dermal fibroblasts (hFibs)
and cartilage tissue-derived chondrocytes. A higher percentage
ofα2–6-sialylatedN-glycans was detected in early passage cells
(24–28 % of sialylated N-glycans) compared with late passage
cells (13–15 %). A major α2–6-sialylated N-glycan structure
detected in adipose-derived hMSCs was that of mono-
sialylated biantennary N-glycan. Similar results were obtained
for the cartilage tissue-derived chondrocytes, Yub621c (28 %
for passage 7 and 5% for passage 28). In contrast, no significant
differences were observed between early and late passage
hMSCs with respect to α2–6-sialylated O-glycan percentages.
These results demonstrate that levels of α2–6-sialylated N-gly-
cans, but not O-glycans, could be used as markers of the differ-
ential potential of hMSCs.
Keywords Mesenchymal stem cell . Glycan .
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Introduction
Humanmesenchymal stem cells (hMSCs) isolated from tissues
such as adipocyte, bone marrow, and umbilical cord blood [1,
2] are attractive cell therapy products (CTPs) for use in regen-
erative medicine based on their abilities to self-renew and to
differentiate into mesenchymal tissue lineages such as osteo-
blasts, cartilage, and adipocytes [3, 4]. This is in addition to
their capacity to alter immune regulatory functions [5].
Indeed, hMSCs have already been applied as CTPs to treat
patients with diseases such as graft-versus-host disease
(GVHD), acute cardiac insufficiency, critical limb ischemia,
osteoarthritis, spinal injury, and diabetes [6, 7]. hMSCs are
obtained from the bone marrow or other tissues of donors from
different backgrounds in terms of age, sex, race etc. These cells
are then expanded in vitro until a required cell number is
reached, and are then transplanted into patients following the
necessary cell treatment protocols. A complicating factor is that
hMSCs are heterogeneous cell populations, whose properties
vary depending on the tissues and donors from which they are
derived, isolation methods, culture conditions, and culture pas-
sages. Therefore, the development of quality control systems
with respect to hMSC handling and use is critical to ensure that
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the appropriate therapeutic effects as well as the safety of CTPs
is achieved. To this end, no cell surface markers are currently
available to evaluate the differentiation potential of stem cells,
this being one of the most important measures of the possible
therapeutic effects of hMSCs.
To identify cell surface glycan markers that might enable the
differentiation potential of hMSCs to be assessed, we build here
on glycome analysis work previously carried out on different
passages of adipose-derived hMSCs using high-density lectin
microarray [8]. We found that α2–6-linked sialic acid (α2–
6Sia)-specific lectins showed stronger binding to early passage
adipose-derived hMSCs with differentiation ability to adipo-
cytes and osteoblasts than did late passage cells without the
ability. Flow cytometry analysis also supported the results ob-
tained by lectin microarray. While similar results were obtained
for bone marrow-derived hMSCs and cartilage tissue-derived
chondrocytes, in the case of human dermal fibroblasts (hFibs),
however, which did not have differentiation potential, but did
possess a high proliferation ability, no binding of α2–6Sia-spe-
cific lectins was observed. This finding demonstrates that the
binding of α2–6Sia-specific lectins is associated with the dif-
ferentiation ability of cells, but not to their capacity to prolifer-
ate. While this may be the case, no information is currently
available concerning the detailed glycan structures of early pas-
sage hMSCs (with differentiation ability) compared to late pas-
sage cells (without the ability to differentiate).
In this study, we provide structural data forN- andO-glycans
derived from early and late passages of human adipose tissue-
derived hMSCs and cartilage tissue-derived chondrocytes. For
quantitative comparison, glycans were liberated by gas-phase
hydrazinolysis from cells fluorescently tagged with 2-
aminopyridine at their reducing terminus, following which of
the derived pyridylaminated (PA-) glycans were purified by
multiple-mode high-performance liquid chromatography
(HPLC). The structures of the PA-glycans were determined
and quantified by HPLC mapping in conjunction with matrix-
assisted laser desorption-ionization time-of-flight mass spec-
trometry (MALDI-TOF MS) and exoglycosidase digestion
analyses. We demonstrate that a higher percentage of α2–6-
sialylatedN-glycans is expressed in early passage hMSCs com-
pared with late passage cells, whereas no significant difference
in the percentage of α2–6-sialylated O-glycans was observed
between early and late passage hMSCs. These results demon-
strate that α2–6-sialylated N-glycans could serve as markers
of the differential potential of hMSCs.
Materials and methods
Cells
hMSCs derived from adipose tissues (Life technologies, lot#:
2117, 2118), cartilage tissue-derived chondrocytes from
polydactylous human fingers (Yub621c, RIKEN CELL
BANK, #: RBRC-HMS0013), and hFibs (ATCC, #: PCS-
201-012, Lot: 58,605,481) were cultured in 10 mL of
MesenPRO RS™Medium (GIBCO, Cat#: 12,746–012) sup-
plemented with 2 mM L-glutamine and 1 % penicillin–strep-
tomycin on 10 cm cell culture dishes. Cells were seeded at 3 x
105 cells per dish and sub-cultured at 80 % confluency as per
the manufacturer’s instructions. 201B7 hiPSCs were cultured
in 2.5 mL of mTeSR1 (STEMCELLTechnologies) on 6-well
plates. Cells were counted with a TC20 Automated Cell
Counter (Bio-Rad).
Materials
Acetonitrile and 1-butanol were obtained from Nacalai
Tesque. Acetic acid was purchased from Wako. Dowex
50WX2 (200–400 mesh, H+ form) was obtained from
Muromachi Technos Co., Ltd. GlycoTAG reagent kit was
from Takara Bio. 2, 5-dihydroxybenzoic acid was from
Bruker Daltonics. The Sep.-PAK Plus C18 cartridge was from
Waters. The Mono Q 5/5 HR column (5.0 x 50 mm), the
PALPAK Type-R column (4.6 x 250 mm) and the Shodex
Asahipak NH2P-50 4D column (4.6 x 150 mm) were from
GE Healthcare Bio-Sciences Corp, Takara Bio, and Showa
Denko, respectively. α2–3, –6- sialidase (Clostridium
perfringens) was from Merck, and α2–3-sialidase
cloned from Salmonella typhimurimum LT2 and
expressed in Escherichia coli was from Takara Bio. β-galac-
tosidase, β-N-acetylhexosaminidase, and α-L-fucosidase
were from ProZyme, Inc. Standard glycans such as core-
fucosylated biantennary N-glycan (Cat#: 4109), asialo (Cat#:
4101), mono- (Cat#: 4122), di- (Cat#: 4123), tri- (Cat#: 4124),
and tetra-sialylated N-glycans (Cat#: 4125). were obtained
from Takara.
Release of N- and O-glycans and pyridylamination
Protein glycans were released from cells by gas-phase
hydrazinolysis [9–11] using Hydraclub Y2100 (J-Oil Mills,
Inc., Tokyo, Japan). Cells (approximately 1 x 106 cells) were
extensively lyophilized in vacuo, and treated with anhydrous
hydrazine at 100 °C for 4 h. After the reaction, the anhydrous
hydrazine was removed in vacuo. The released glycans were
re-N-acetylated with addition of acetic anhydride in a
saturated sodium bicarbonate solution, desalted with
Dowex 50WX2, and lyophilized [9]. The reducing ends
of the liberated glycans were tagged with 2-aminopyridine
using GlycoTAG (Takara Bio) and the GlycoTAG re-
agent kit [12–14]. The bulk of excess reagents in the
reaction mixture was removed by phenol/chloroform ex-
traction [15] and subsequent solid-phase extraction using a




Anion-exchange HPLC was performed on a Mono-Q column
at a flow rate of 1.0 ml/min using two eluents, A and B. Eluent
A was distilled water titrated to pH 9.0 with 1 M aqueous
ammonia, and eluent B was a 0.5 M ammonia acetate solution
titrated to pH 9.0. The column was equilibrated with 100 %
eluent A. After injecting a sample, the proportion (v/v) of
eluent B was increased linearly to 10 % (3 min), then to
40% (14 min), and finally to 100 % (5 min). The fluorescence
of the eluted PA-glycans was detected with excitation and
emission wavelengths of 310 nm and 380 nm, respectively.
Size-fractionation HPLC was performed on a Shodex
Asahipak NH2P-50 4D column (4.6 x 150 mm) at a flow rate
of 1.0 ml/min at 25 °C with a gradient system: two eluents, C
and D, were used, where eluent C was acetonitrile: water:
acetic acid (970:70:3, v/v/v) titrated to pH 7.0 with 7 M aque-
ous ammonia, and eluent D was acetonitrile:water:acetic acid
(200:800:3, v/v/v) titrated to pH 7.0 with 7 M aqueous ammo-
nia. The column was equilibrated with 95 % eluent C and 5 %
eluent D. After injection of a sample solution, the proportion
(v/v) of eluent D was increased linearly from 5 % to 33 %
(3 min), then to 100 % (75 min). Glycan fluorescence was
detected at excitation and emission wavelengths of 320 nm
and 400 nm, respectively.
Reversed-phase HPLC was performed on a PALPAK
Type-R column (4.6 x 250 mm) with two eluents, E and F,
where eluent E was 100 mM ammonium acetate, pH 4.0, and
eluent F was 100 mM ammonium acetate, pH 4.0, containing
0.5 % (v/v) 1-butanol. The columnwas equilibrated with 75%
eluent E and 25 % eluent F. After injection of a sample, the
proportion (v/v) of eluent F was increased linearly from 25 %
to 100 % (60 min) at a flow rate of 1.0 ml/min at 25 °C.
Glycan fluorescence was detected at excitation and emission
wavelengths of 320 nm and 400 nm, respectively.
MS
The purified PA-glycans were subjected to analysis by
MALDI-TOF MS with an Ultraflex mass spectrometer
(Bruker Daltonics, Bremen, Germany), equipped with a 337-
nm nitrogen laser, and set at 20 kV extraction voltage. 2, 5-
dihydroxybenzoic acid (1 mg/ml in 30% ethanol) was used as
the matrix. Analyses were carried out in reflector mode over a
mass range of m/z 0 to 2000, or 1000 to 4000 in the positive
ion mode. Each spectrum was measured by 150 laser shots.
Quantification of PA-saccharides
Each PA-glycan was quantified by the peak area compared
with that corresponding to an appropriate authentic standard
separated under the same HPLC conditions. PA-GlcNAc was
used as the authentic calibration standard. Relative yields were
expressed as percentages compared to the total amounts of N-
linked or O-linked glycans prepared from each of the cell
samples.
Exoglycosidase treatment
Exoglycosidase treatment of PA-glycans was carried out by
using α2–3, –6-sialidase (C. perfringens: Merck), α2–3-
sialidase (S. typhimurimum LT2, recombinant, E. coli:
Takara Bio), β-galactosidase (Jack bean: ProZyme, Inc.), β-
N-acetylhexosaminidase (Jack bean: ProZyme, Inc.), or α-L-
fucosidase (bovine kidney: ProZyme, Inc.). PA-glycan was
treated with the enzyme (50 mU) in 20 μl of 50 mM ammo-
nium acetate buffer (β-galactosidase: pH 3.5, α2–3, −6-
sialidase and β-N-acetylhexosaminidase: pH 5.0, α2–3-
sialidase andα-L-fucosidase: pH 5.5), at 37 °C for appropriate
periods (0.5 h for α2–3, –6-sialidase and α2–3-
sialidase; 20 h for others). The enzyme reaction was termi-
nated by heating at 99.9 °C for 5 min.
Analysis of the Sia linkage type
The sialic acid linkage type was determined by its sensitivity
to α2–3, −6-sialidase (C. perfringens, Merck) and α2–3-
sialidase (S. typhimurimum LT2, recombinant, E. coli,
Takara Bio) treatment. Each acidic saccharide was treated
with both sialidases, and the products were analyzed by
anion-exchange HPLC using a Mono-Q column. If an acidic
glycan has the α2–3 type of sialic acid linkage, its retention
time should decrease after digestion both with α2–3, −6 and
α2–3-sialidases. In contrast, if the glycan has the α2–6 type
linkage, its retention time should be preserved after α2–3-
sialidase treatment. When all Sia residues are removed
by the action of α2–3, −6-sialidase, a neutral glycan
should be generated.
Results
Basic strategy of glycan analysis of adipose-derived
hMSCs
N- and O-glycans were liberated by gas-phase hydrazinolysis
from early and late passages of lyophilized adipose-derived
hMSCs. Two lots of early and late passages of adipose-de-
rived hMSCs (lot#: 2117, passage 5 (P5) and P26;
lot#: 2118, P3 and P28) were analyzed to confirm the
reproducibility and consistency of the results. Whole glycans
comprising both intracellular (ER and Golgi) and surface
membranous fractions were re-N-acetylated and labeled with
2-aminopyridine.
The derived PA-glycans were first separated by anion-
exchange HPLC (Fig. 1a). Neutral glycans, which passed
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through the column, were pooled and designated the BN″ frac-
tion. Adsorbed anionic glycans were fractionated and designat-
ed the BA1-A6^ fractions (according to the order of elution,
Fig. 1a). These fractions were then subjected to size-
fractionation HPLC (for fractions N, A1 and A4, see Fig. 1b).
Each peak was fractioned, and when necessary, the eluate was
further purified by reversed-phase HPLC (chromatogram not
shown). Each purified PA-glycan was quantified on the basis of
fluorescence intensity relative to an appropriate authentic stan-
dard (PA-GlcNAc).
The purified neutral glycans (No.1–16 and 28–29) were
analyzed by MALDI-TOF MS and reversed-phase HPLC
(chromatogram not shown), and when necessary, were treated
with glycosidases to confirm their structure. As a result, un-
ambiguous assignment was made for all glycans, with 16 N-
glycans and 2 O-glycans identified as neutral glycans in four
different cell lines (Tables 1 and 2).
Acidic glycans (A1-A6 fractions) were analyzed by a com-
bination of sialidase digestion, MALDI-TOF MS and
Fig. 1 Comparison of HPLC profiles of glycans derived from adipose-
derived hMSCs lot#: 2118 P3 and P28. a Anion-exchange HPLC
profiles. S0, S1, S2, and S3 are standard N-glycans containing 0, 1, 2,
and 3 Sia residues. b Size-fractionation HPLC profiles of neutral fraction
(N), monosialylated N-glycan fraction (A1), and disialylated N-glycan
fraction (A4). Following anion-exchange HPLC, further purification
was performed. Each peak was pooled, and when necessary, was
further purified by reversed-phase HPLC, or subjected to further
structural analysis. Arrowheads indicate the peak numbers
Table 1 List of N-glycans identified in adipose-derived hMSCs
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reversed-phase HPLC. After digestion with universal
α2–3, −6-sialidase, the products were passed through a
Mono-Q column, analyzed by MALDI-TOF MS and
reversed-phase HPLC. Their structures were determined as
described above. The type of linkage of each sialic acid was
determined by susceptibility to two sialidases, i.e., α2–3-spe-
cific sialidase and the universal α2–3, −6-sialidase. For exam-
ple, the structure of α2–6-disialylated, core-fucosylated
biantennary N-glycan, A4–14-1, derived from adipose-
derived hMSCs (Lot#:2117 P5) was determined as follows.
When A4–14-1 was treated with α2–3, −6-sialidase
(C. perfringens, Merck) and analyzed by MALDI-TOF MS,
the glycan was determined as the monofucosylated
biantennary glycan (m/z, 1865.5 [M + H]+ in positive mode),
which exactly matched with the elution time of the standard
core-fucosylated biantennary N-glycan by reversed-phase
HPLC. On the other hand, when A4–14-1 was treated with
α2–3-sialidase, no Sia was released, demonstrating that the
linkage mode of Sia of A4–14-1 is α2–6Sia. Disialylation
on both branches of biantennary N-glycans could be con-
firmed by comparing with the retention time with standard
glycans of asialo, mono-, di-, tri-, and tetra-sialylated N-gly-
cans in an anion-exchange chromatography.
As a result, 9 and 8 acidic N-glycans were identified from
P5 and P26 of adipose-derived hMSCs (lot#: 2117), respec-
tively, while 11 and 8 acidic N-glycans were identified from
lot#: 2118 P3 and P28, respectively (Table 1). Five acidic O-
glycans were identified in A1–6 fractions obtained from
four different cell lines (Table 2). Finally, 25, 24, 27,
and 24 N-glycans were identified from P5 and P26 of
adipose-derived hMSCs from lot#: 2117, and P3 and
P28 of adipose-derived hMSCs from lot#: 2118, respectively
(Table 1). Seven O-glycan structures were identified from the
cell lines (Table 2).
Table 2 List of O-glycans identified in adipose-derived hMSCs
1 Fraction number. The first, second, and third alphanumerical numbers correspond to the fraction number of anion-exchange HPLC, size-fractionation
HPLC, and reversed-phase HPLC, respectively.
The numbers in parenthesis show percentage as a function of the total amount of O-glycans.
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Comparative analysis of N- and O-glycans between early
and late passages of adipose-derived hMSCs
We next compared the percentage of each glycan derived from
early and late passages of adipose-derived hMSCs, taking the
total amounts of N- or O-glycans prepared from each sample
to be 100 % (Fig. 2). Among N-glycans, high-mannose type
N-glycans (No.1–12) accounted for a substantial fraction in
both the early and late passages of these cells. Interestingly,
the expression patterns of high-mannose type N-glycans were
significantly different between the two lots. In terms of No. 8
glycan, for example, early passage cells (P5) of adipose-
derived hMSCs (lot#: 2117) exhibited higher percentage than
late passage cells (P26), whereas late passage cells (P28) gave
higher percentage than early passage cells (P3) in lot#: 2118.
In terms of No. 11 glycan, late passage cells (P26) exhibited
much higher percentage than early passage cells (P5) of
adipose-derived hMSCs (lot#: 2117), whereas early passage
cells (P3) gave higher percentage than late passage cells (P28)
in lot#: 2118.
Asialo complex type (No.13–16) and sialylated N-glycans
(No. 17–27) were also detected in significant amounts. A hy-
brid type N-glycan was also observed (No. 23) (Table 1).
Among the O-glycans, interestingly, a high percentage of
sialylated O-glycans was detected in adipose-derived hMSCs
(Fig. 3). Sialyl Tn (No. 32) gave the highest percentage in both
early and late passages of adipose-derived hMSCs
(Fig. 2 and Table 2). Disialyl T (Siaα2–3Galβ1–
3(Siaα2–6)GalNAc, No. 34) was also detected in signif-
icant amounts. Core1 (Galβ1–3GalNAc, No. 28) and core2
[Galβ1-4GlcNAcβ1–6(Galβ1–3)GalNAc, No. 29], and their
sialylated forms (No. 30,31, 33, 34) were also detected. The
percentage of sialyl Tn (Siaα2–6GalNAc, No. 32) was ob-
served to be higher in late passage cells (lot#: 2117 P26 and
lot#: 2118 P28) compared with early passage cells (lot#: 2117
P5 and lot#: 2118 P3).
Comparative analysis of N- and O-glycans
of adipose-derived hMSCs with other cell types
Overall signatures of N- and O-glycans of adipose-derived
hMSCs were compared to hiPSCs (cell line 201B7) as a rep-
resentative of human pluripotent stem cells, and to hFibs as a
representative of somatic cells, in addition to another type of
somatic stem cell, cartilage tissue-derived chondrocytes
(Yub621c, P7 and P28) (Fig. 3). All of the cells gave similar
patterns of N-glycan types. As described above, high-
mannose type N-glycans gave the highest percentage among
Fig. 2 Comparison of N- and O-glycans prepared from adipose-derived hMSCs lot#: 2117 and lot#: 2118. Each glycan is expressed as a percentage of
the total amount of N- or O-glycans obtained from each sample (taken as 100 %). Glycan numbers correspond to those used in Tables 1 and 2
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the types ofN-glycans that were present. Asialo and sialylated
N-glycans were also observed.
In contrast, the overall O-glycan signatures were different
depending on the cell types under consideration. Interestingly,
adipose-derived hMSCs gave a high percentage of sialylated
O-glycans (average 84 %) relative to hiPSCs (39 %), hFibs
(59 %), and cartilage-derived chondrocytes (31 %).
α2–6-sialylatedN-glycans, but notO-glycans, are markers
of the differentiation potential of stem cells
We subsequently focused our attention on sialylation, since
α2–6Sia-binding lectins showed stronger binding to early pas-
sage hMSCs derived from adipocytes and bone marrow than
their corresponding late passage cells, as previously reported
[8]. Figure 4 summarizes the Sia linkage type in N- and O-
glycans, where Bα2–3Sia^ and Bα2–6Sia^ indicate N- or O-
glycans containing α2–3Sia and α2–6Sia, respectively, and
Bα2–3Sia + α2–6Sia^ indicate N- or O-glycans containing
both α2–3Sia and α2–6Sia.
In terms of N-glycans, 201B7 hiPSCs expressed exclusive-
ly α2–6Sia (100 %), whereas, in contrast, hFibs expressed
mostly α2–3Sia (1 % for α2–6Sia) [17]. In agreement with
the previous report [8], the percentage of α2–6-sialylated N-
glycans (Fig. 4, black and grey) was indeed higher in early
passage adipose-derived hMSCs (29 % for lot#: 2117 P5,
25 % for lot#: 2118 P3) than for corresponding late passage
cells (14 % for lot#: 2117 P26, 16 % for lot#: 2118 P28).
Similarly, early passage cartilage tissue-derived chondrocytes
(29 % for P7) expressed a higher percentage of α2–6-
sialylated N-glycans than corresponding late passage cells
(5 % for P28). A major α2–6-sialylated N-glycan structure
detected in adipose-derived hMSCs and cartilage tissue-
derived chondrocytes was Bmono-sialylated biantennary N-
glycan^ (Fig. 2 and Table 1). O-glycans containing α2–6Sia
such as sialyl Tn (Siaα2–6GalNAc) and disialyl T (Siaα2–
3Galβ1–3(Siaα2–6)GalNAc) were also detected inO-glycans
(Table 2). However, no significant relationship was observed
between the differentiation potential of stem cells and
the Sia linkage mode of O-glycans. Taken together,
these results clearly demonstrate that α2–6-sialylated N-gly-
cans, but not O-glycans, are markers of the differentiation
potential of stem cells.
Discussion
Previously, we performed a quantitative glycome analysis
targeting both N- and O-glycans derived from 201B7
hiPSCs and hFibs representing undifferentiated and differen-
tiated cells, respectively, using the same strategy described in
the present report [17]. A dramatic glycome shift became
Fig. 3 Summary of glycan type. Comparison of the glycan type and
proportion in N- and O-glycans prepared from hiPSCs, adipose-derived
hMSCs (lot#: 2117) P5 and P26, adipose-derived hMSCs (lot#: 2118) P3
and P28, cartilage tissue-derived chondrocytes (Yub621c) P7 and P28, and
hFibs. Results were calculated based on the data in Tables 1 and 2
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evident upon conversion from differentiated hFibs to undiffer-
entiated hiPSCs. One of the most significant changes was the
Sia linkage mode, which for N-glycans of 201B7 hiPSCs was
found to consist exclusively ofα2–6Sia, whereas that of hFibs
was mostly of the α2–3Sia type [17]. Recently, using the
systematic glycan profiling system called high-density lectin
microarray, we found that α2–6Sia-specific lectins (SNA,
SSA, TJA1, and rPSL1a) show stronger binding to early pas-
sage cells (with differentiation ability) than late passage cells
(without this ability) [8]. Similar results were observed for
bone marrow-derived hMSCs and cartilage tissue-derived
chondrocytes. Furthermore, the removal of Sia by sialidase
treatment significantly reduced the differentiation efficiency
of hMSCs. Therefore, we proposed that α2–6-sialylation could
be a functional marker of the differentiation potential of stem
cells. In the present report, we have performed a structural and
quantitative analysis of the glycome of early and late passages
of adipose- and cartilage tissue-derived chondrocytes using
HPLC analysis combined with MS. We clearly demonstrate
that the percentage of α2–6Sia-containing N-glycans, but not
O-glycans, was found to be higher in early passage cells than
late passage cells. Therefore, α2–6-sialylaed N-glycans could
serve as markers of the differentiation potential of stem cells.
SNA and SSA, but not TJA1 and rPSL1a, bound to bovine
submaxillary mucins expressing sTn as described in the pre-
vious report [8]. Therefore, sTn could be target glycans for
SNA and SSA, although sTn showed no relationship with the
differentiation capacity of hMSC. In this sense, TJA1 and
rPSL1a without the binding affinity to sTn might be better
probes for the purpose of the evaluation of the differentiation
capacity of hMSCs.
The expression of α2–6-sialyltransferase (ST6Gal-I) has
been shown to play an important role in the regulation of
cellular pluripotency in human pluripotent stem cells
[18–20]. Therefore, the key phenomena might be the changes
of the expression of ST6Gal-I. ST6Gal-I catalyzes the addition
of terminal α2–6Sia to N-glycans, but not O-glycans. This
might be the reason why α2–6–sialylation on N-glycans, but
not O-glycans, changes depending on the differentiation po-
tential of hMSCs. Combined with our findings showing
that α2–6Sia is dominant on N-glycans of hiPSCs and
correlates with the differentiation capacity of cells, it
seems that the expression of α2–6-sialylated N-glycans is as-
sociated with Bstemness^.
What are the roles of α2–6Sia in stem cell functions?
Previously we showed that α5integrin with 14 N-glycosylation
Fig. 4 Linkage mode of Sia. Comparison of the Sia linkage type inN- and
O-glycans prepared from hiPSCs, adipose-derived hMSCs (lot#: 2117) P5
and P26, adipose-derived hMSCs (lot#: 2118) P3 and P28, cartilage tissue-
derived chondrocytes (Yub621c) P7 and P28, and hFibs. Data are
expressed as a percentage of the total amount of sialylated N- orO-glycans
obtained from each sample (taken as 100%). Results were calculated based
on the data provided in Tables 1 and 2
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sites is one of the carrier proteins of α2–6Sia in cartilage tissue-
derived chondrocytes [8]. α5β1integrin is a well-known fibro-
nectin receptor, and its interaction with fibronectin is essential
for cell migration and proliferation, for the activation of intra-
cellular signaling pathways, and cytoskeletal formation [21].
Therefore, α2–6Sia on α5integrin could modulate interactions
with matrix components such as fibronectin and regulate the
differentiation potency of stem cells. Further studies are re-
quired to understand the roles of α2–6Sia in this process.
The development of novel markers to evaluate the properties
of hMSCs is keenly required for the realization of safe stem
cell-based therapy, with such cells being used as hCTPs in
regenerative medicine to treat various diseases. Here we have
provided structural evidence showing that the expression of
α2–6-sialylated N-glycans varies depending on the differentia-
tion potential of stem cells. Rapid, sensitive, and nondestructive
process analytical testing (PAT) is essential for the stable supply
of hMSCs, which could be used for monitoring during the cell
production process. The quality control system to assess
hMSCs for use as CTPs will become increasingly more impor-
tant and stringent from the viewpoint of regulatory science.
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